AIMS: To examine the relationship of anxiety and depression symptoms with treatment outcomes (treatment discontinuation, rates of ongoing use of illicit drugs and likelihood of preterm delivery) in opioid-dependent pregnant women and describe their use of psychotropic medications. DESIGN AND SETTING: Secondary data analysis from a randomized clinical trial of treatment for opioid dependence during pregnancy. PARTICIPANTS: A total of 175 opioid-dependent pregnant women, of whom 131 completed treatment. MEASUREMENTS: Symptoms of anxiety and depression were captured with the 15-item Mini International Neuropsychiatric Interview (MINI) screen. Use of illicit drugs was measured by urine drug screening. Preterm delivery was defined as delivery prior to 37 weeks' gestation. Self-reported use of concomitant psychotropic medication at any point during the study was recorded. FINDINGS: Women reporting only anxiety symptoms at study entry were more likely to discontinue treatment [adjusted odds ratio (OR) = 4.56, 95% confidence interval (CI) : 1.91-13.26, P = 0.012], while those reporting only depression symptoms were less likely to discontinue treatment (adjusted OR = 0.14, 95% CI : 0.20-0.88, P = 0.036) compared to women who reported neither depression nor anxiety symptoms. No statistically significant between-group differences were observed for ongoing illicit drug use or preterm delivery. A majority (61.4%) of women reported use of concomitant psychotropic medication at some point during study participation. CONCLUSIONS:Opioid agonist-treated pregnant patients with co-occurring symptoms of anxiety require additional clinical resources to prevent premature discontinuation.
RCT Entities:
AIMS: To examine the relationship of anxiety and depression symptoms with treatment outcomes (treatment discontinuation, rates of ongoing use of illicit drugs and likelihood of preterm delivery) in opioid-dependent pregnant women and describe their use of psychotropic medications. DESIGN AND SETTING: Secondary data analysis from a randomized clinical trial of treatment for opioid dependence during pregnancy. PARTICIPANTS: A total of 175 opioid-dependent pregnant women, of whom 131 completed treatment. MEASUREMENTS: Symptoms of anxiety and depression were captured with the 15-item Mini International Neuropsychiatric Interview (MINI) screen. Use of illicit drugs was measured by urine drug screening. Preterm delivery was defined as delivery prior to 37 weeks' gestation. Self-reported use of concomitant psychotropic medication at any point during the study was recorded. FINDINGS:Women reporting only anxiety symptoms at study entry were more likely to discontinue treatment [adjusted odds ratio (OR) = 4.56, 95% confidence interval (CI) : 1.91-13.26, P = 0.012], while those reporting only depression symptoms were less likely to discontinue treatment (adjusted OR = 0.14, 95% CI : 0.20-0.88, P = 0.036) compared to women who reported neither depression nor anxiety symptoms. No statistically significant between-group differences were observed for ongoing illicit drug use or preterm delivery. A majority (61.4%) of women reported use of concomitant psychotropic medication at some point during study participation. CONCLUSIONS: Opioid agonist-treated pregnant patients with co-occurring symptoms of anxiety require additional clinical resources to prevent premature discontinuation.
Authors: Geoffrey M Curran; JoAnn E Kirchner; Mark Worley; Craig Rookey; Brenda M Booth Journal: J Behav Health Serv Res Date: 2002-05 Impact factor: 1.505
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Hendrée E Jones; Gabriele Fischer; Sarah H Heil; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Kevin E O'Grady; Amelia M Arria Journal: Addiction Date: 2012-11 Impact factor: 6.526
Authors: Timothy Nielsen; Dana Bernson; Mishka Terplan; Sarah E Wakeman; Amy M Yule; Pooja K Mehta; Monica Bharel; Hafsatou Diop; Elsie M Taveras; Timothy E Wilens; Davida M Schiff Journal: Addiction Date: 2019-11-13 Impact factor: 6.526
Authors: Jason R Pryor; Faouzi I Maalouf; Elizabeth E Krans; Robert E Schumacher; William O Cooper; Stephen W Patrick Journal: Arch Dis Child Fetal Neonatal Ed Date: 2017-01-10 Impact factor: 5.747
Authors: Davida M Schiff; Timothy Nielsen; Mishka Terplan; Malena Hood; Dana Bernson; Hafsatou Diop; Monica Bharel; Timothy E Wilens; Marc LaRochelle; Alexander Y Walley; Thomas Land Journal: Obstet Gynecol Date: 2018-08 Impact factor: 7.661
Authors: Davida M Schiff; Timothy C Nielsen; Bettina B Hoeppner; Mishka Terplan; Scott E Hadland; Dana Bernson; Shelly F Greenfield; Judith Bernstein; Monica Bharel; Julia Reddy; Elsie M Taveras; John F Kelly; Timothy E Wilens Journal: Am J Obstet Gynecol Date: 2021-04-15 Impact factor: 10.693